Janux Therapeutics JANX -48.96% ▼ stock plunged 40% in Tuesday’s pre-market trading after the clinical-stage biopharmaceutical company announced “positive” interim results from its JANX007 Phase 1 clinical program in patients with metastatic castration-resistant prostate cancer (mCRPC). While the company stated that the efficacy and safety profile were “encouraging,” investors appeared unimpressed. Following the update, several analysts lowered their price targets for JANX stock.
https://www.tipranks.com/news/why-is-janux-therapeutics-stock-janx-crashing-today
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.